{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:46:25Z","timestamp":1777340785089,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40264-017-0563-9","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T14:50:53Z","timestamp":1498488653000},"page":"911-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Patients\u2019 Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana"],"prefix":"10.1007","volume":"40","author":[{"given":"George Tsey","family":"Sabblah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delese Mimi","family":"Darko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hudu","family":"Mogtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"H\u00e4rmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"563_CR1","doi-asserted-by":"crossref","DOI":"10.1002\/9781118344828","volume-title":"Textbook of pharmacoepidemiology","author":"BL Strom","year":"2013","unstructured":"Strom BL, Kimmel SE, Hennessy S. Textbook of pharmacoepidemiology. New York: Wiley; 2013."},{"issue":"1","key":"563_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11594320-000000000-00000","volume":"35","author":"F Hunsel van","year":"2012","unstructured":"van Hunsel F, H\u00e4rmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45\u201360.","journal-title":"Drug Saf."},{"issue":"8","key":"563_CR3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689\u2013703.","journal-title":"Drug Saf."},{"key":"563_CR4","unstructured":"Herxheimer A, Crombag R, Alves TL. Direct patient reporting of adverse drug reactions a fifteen-country survey and literature review. Health Action International. 2010. \n                        http:\/\/consumers.cochrane.org\/sites\/consumers.cochrane.org\/files\/public\/uploads\/10%20May%202010%20Report%20Direct%20Patient%20Reporting%20of%20ADRs.pdf\n                        \n                    . Accessed 21 July 2016."},{"issue":"6","key":"563_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-014-0162-y","volume":"37","author":"F Margraff","year":"2014","unstructured":"Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409\u201319.","journal-title":"Drug Saf."},{"issue":"4","key":"563_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00002018-200326040-00001","volume":"26","author":"K Grootheest van","year":"2003","unstructured":"van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003;26(4):211\u20137.","journal-title":"Drug Saf."},{"issue":"3","key":"563_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pds.2092","volume":"20","author":"F Hunsel van","year":"2011","unstructured":"van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case\u2013control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286\u201391.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"563_CR8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/pds.3687","volume":"24","author":"L Rolfes","year":"2015","unstructured":"Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals: differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24(2):152\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"563_CR9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14740338.6.6.705","volume":"6","author":"IW Hammond","year":"2007","unstructured":"Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Expert Opin Drug Saf. 2007;6(6):705\u201312.","journal-title":"Expert Opin Drug Saf."},{"issue":"7","key":"563_CR10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.15252\/embr.201642616","volume":"17","author":"K Weigmann","year":"2016","unstructured":"Weigmann K. Consumer reporting of adverse drug reactions: systems that allow patients to report side effects of the drugs they are taking have yielded valuable information for improving drugs safety and health care. EMBO Rep. 2016;17(7):949\u201352.","journal-title":"EMBO Rep."},{"issue":"4","key":"563_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-200326040-00002","volume":"26","author":"RBM Fernandopulle","year":"2003","unstructured":"Fernandopulle RBM, Weerasuriya K. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world. Drug Saf. 2003;26(4):219\u201325.","journal-title":"Drug Saf."},{"issue":"2","key":"563_CR12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2006.02746.x","volume":"63","author":"A Blenkinsopp","year":"2007","unstructured":"Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148\u201356.","journal-title":"Br J Clin Pharmacol."},{"issue":"5","key":"563_CR13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-2125.2011.03990.x","volume":"72","author":"C Anderson","year":"2011","unstructured":"Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806\u201322.","journal-title":"Br J Clin Pharmacol."},{"issue":"8","key":"563_CR14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00002018-200730080-00003","volume":"30","author":"BA Golomb","year":"2007","unstructured":"Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669\u201375.","journal-title":"Drug Saf."},{"issue":"3","key":"563_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7861\/clinmedicine.2-3-227","volume":"2","author":"RL Tattersall","year":"2002","unstructured":"Tattersall RL. The expert patient: a new approach to chronic disease management for the twenty-first century. Clin Med. 2002;2(3):227\u20139.","journal-title":"Clin Med."},{"key":"563_CR16","volume-title":"The patient will see you now: the future of medicine is in your hands","author":"E Topol","year":"2015","unstructured":"Topol E. The patient will see you now: the future of medicine is in your hands. New York: Basic Books; 2015."},{"key":"563_CR17","unstructured":"European Commission. Regulation (EU) No. 1235\/2010 of the European Parliament and of the Council of 15 December 2010. \n                        http:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2010_1235\/reg_2010_1235_en.pdf\n                        \n                    . Accessed 16 June 2016."},{"key":"563_CR18","doi-asserted-by":"crossref","first-page":"c5344","DOI":"10.1136\/bmj.c5344","volume":"341","author":"R Watson","year":"2010","unstructured":"Watson R. New rules will allow EU patients to report drug concerns directly. BMJ. 2010;341:c5344.","journal-title":"BMJ."},{"issue":"3","key":"563_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11586620-000000000-00000","volume":"34","author":"JJ Borg","year":"2011","unstructured":"Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187\u201397.","journal-title":"Drug Saf."},{"issue":"11","key":"563_CR20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40264-016-0453-6","volume":"39","author":"C Matos","year":"2016","unstructured":"Matos C, H\u00e4rmark L, van Hunsel F. Patient reporting of adverse drug reactions: an international survey of national competent authorities\u2019 views and needs. Drug Saf. 2016;39(11):1105\u201316.","journal-title":"Drug Saf."},{"issue":"3","key":"563_CR21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0975-7406.116824","volume":"5","author":"R Elkalmi","year":"2013","unstructured":"Elkalmi R, Hassali MA, Al-Lela OQ, Jawad Awadh AI, Al-Shami AK, Jamshed SQ. Adverse drug reactions reporting: knowledge and opinion of general public in Penang, Malaysia. J Pharm Bioallied Sci. 2013;5(3):224\u20138.","journal-title":"J Pharm Bioallied Sci."},{"key":"563_CR22","doi-asserted-by":"publisher","unstructured":"Reis CD, Veiga CE, Martins JJ. Pharmacovigilance in Cabo Verde: measuring the awareness and knowledge of consumers. J Pharmacovigil. 2016;4:200. doi:\n                        10.4172\/2329-6887.1000200\n                        \n                    .","DOI":"10.4172\/2329-6887.1000200"},{"issue":"2","key":"563_CR23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2710.2011.01273.x","volume":"37","author":"H Fortnum","year":"2012","unstructured":"Fortnum H, Lee AJ, Rupnik B, Avery A. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161\u20135.","journal-title":"J Clin Pharm Ther."},{"issue":"7","key":"563_CR24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-015-1867-2","volume":"71","author":"C Matos","year":"2015","unstructured":"Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the pharmacovigilance system? A Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883\u201390.","journal-title":"Eur J Clin Pharmacol."},{"issue":"10","key":"563_CR25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5694\/mja13.10069","volume":"199","author":"J Robertson","year":"2013","unstructured":"Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684\u20136.","journal-title":"Med J Aust."},{"issue":"11","key":"563_CR26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00228-010-0865-7","volume":"66","author":"F Hunsel van","year":"2010","unstructured":"van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143\u201350.","journal-title":"Eur J Clin Pharmacol."},{"key":"563_CR27","unstructured":"WHO-UMC. Countries participating in the WHO Programme for International Drug Monitoring, with year of joining. 2016. \n                        http:\/\/www.who-umc.org\/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442\n                        \n                    . Accessed 30 July 2016."},{"key":"563_CR28","unstructured":"Ayamgha B. FDA launches patients safety programme. 2016. \n                        http:\/\/www.ghananewsagency.org\/health\/fda-launches-patients-safety-programme-104704\n                        \n                    . Accessed 30 July 2016."},{"key":"563_CR29","unstructured":"Santos A. Direct patient reporting in the European Union a snapshot of reporting systems in seven member states. 2015. \n                        http:\/\/apps.who.int\/medicinedocs\/documents\/s22088en\/s22088en.pdf\n                        \n                    . Accessed 30 July 2016."},{"issue":"3","key":"563_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40264-013-0021-2","volume":"36","author":"L Hazell","year":"2013","unstructured":"Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ. How do patients contribute to signal detection? Drug Saf. 2013;36(3):199\u2013206.","journal-title":"Drug Saf."},{"issue":"10","key":"563_CR31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","volume":"39","author":"L H\u00e4rmark","year":"2016","unstructured":"H\u00e4rmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39(10):883\u201390.","journal-title":"Drug Saf."},{"issue":"2","key":"563_CR32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","volume":"50","author":"I Ajzen","year":"1991","unstructured":"Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50(2):179\u2013211.","journal-title":"Organ Behav Hum Decis Process."},{"key":"563_CR33","unstructured":"Ajzen I. Constructing a theory of planned behavior questionnaire. 2006. \n                        http:\/\/people.umass.edu\/~aizen\/pdf\/tpb.measurement.pdf\n                        \n                    . Accessed 11 Dec 2016."},{"issue":"1","key":"563_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2011.03944.x","volume":"72","author":"P Gavaza","year":"2011","unstructured":"Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Influence of attitudes on pharmacists\u2019 intention to report serious adverse drug events to the Food and Drug Administration. Br J Clin Pharmacol. 2011;72(1):143\u201352.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"563_CR35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.sapharm.2010.09.001","volume":"7","author":"P Gavaza","year":"2011","unstructured":"Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Examination of pharmacists\u2019 intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. Res Soc Adm Pharm. 2011;7(4):369\u201382.","journal-title":"Res Soc Adm Pharm."},{"issue":"6","key":"563_CR36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/qshc.2008.030700","volume":"19","author":"JG Wakefield","year":"2010","unstructured":"Wakefield JG, McLaws M-L, Whitby M, Patton L. Patient safety culture: factors that influence clinician involvement in patient safety behaviours. BMJ Qual Saf. 2010;19(6):585\u201391.","journal-title":"BMJ Qual Saf."},{"issue":"4","key":"563_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jonm.12467","volume":"25","author":"A Angelis","year":"2017","unstructured":"Angelis A, Pancani L, Steca P, Colaceci S, Giusti A, Tibaldi L, Alvaro R, Ausili D, Vellone E. Testing an explanatory model of nurses\u2019 intention to report adverse drug reactions in hospital settings. J Nurs Manag. 2017;25(4):307\u201317. doi:\n                        10.1111\/jonm.12467\n                        \n                    .","journal-title":"J Nurs Manag."},{"issue":"1","key":"563_CR38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09540120802017628","volume":"21","author":"BT Mausbach","year":"2009","unstructured":"Mausbach BT, Semple SJ, Strathdee SA, Patterson TL. Predictors of safer sex intentions and protected sex among heterosexual HIV-negative methamphetamine users: an expanded model of the theory of planned behavior. AIDS Care. 2009;21(1):17\u201324.","journal-title":"AIDS Care."},{"issue":"1","key":"563_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2006.09.026","volume":"65","author":"M Whitby","year":"2007","unstructured":"Whitby M, Pessoa-Silva CL, McLaws ML, Allegranzi B, Sax H, Larson E, Seto WH, Donaldson L, Pittet D. Behavioural considerations for hand hygiene practices: the basic building blocks. J Hosp Infect. 2007;65(1):1\u20138.","journal-title":"J Hosp Infect."},{"key":"563_CR40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/PPA.S78628","volume":"9","author":"L Gu\u00e9nette","year":"2015","unstructured":"Gu\u00e9nette L, Lauzier S, Guillaumie L, Gigu\u00e8re G, Gr\u00e9goire J-P, Moisan J. Patients\u2019 beliefs about adherence to oral antidiabetic treatment: a qualitative study. Patient Prefer Adherence. 2015;9:413\u201320.","journal-title":"Patient Prefer Adherence."},{"key":"563_CR41","unstructured":"Ghana Statistical Service (GSS), Ghana Health Service (GHS), and ICF International. 2015. Ghana Demographic and Health Survey 2014. \n                        http:\/\/dhsprogram.com\/pubs\/pdf\/FR307\/FR307.pdf\n                        \n                    . Accessed 13 Apr 2017."},{"key":"563_CR42","unstructured":"Food and Drugs Authority. DrugLens. 2016. \n                        http:\/\/fdaghana.gov.gh\/images\/stories\/pdfs\/DrugLens\/DrugLensissue4.pdf\n                        \n                    . Accessed 12 Nov 2016."},{"issue":"4","key":"563_CR43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"HH Ampadu","year":"2016","unstructured":"Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, Leufkens HG, Dodoo AN. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae. Drug Saf. 2016;39(4):335\u201345.","journal-title":"Drug Saf."},{"issue":"4","key":"563_CR44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4314\/gmj.v48i4.4","volume":"48","author":"GT Sabblah","year":"2014","unstructured":"Sabblah GT, Akweongo P, Darko D, Dodoo ANO, Sulley AM. Adverse drug reaction reporting by doctors in a developing country: a case study from Ghana. Ghana Med J. 2014;48(4):189\u201393.","journal-title":"Ghana Med J."},{"issue":"2","key":"563_CR45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","volume":"22","author":"MJ Alomar","year":"2014","unstructured":"Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83\u201394.","journal-title":"Saudi Pharm J."},{"issue":"20","key":"563_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15200","volume":"15","author":"AJ Avery","year":"2011","unstructured":"Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK \u201cYellow Card Scheme\u201d: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1\u2013234.","journal-title":"Health Technol Assess."},{"key":"563_CR47","unstructured":"World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. 2006. \n                        http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/Pharmacovigilance_B.pdf?ua=1\n                        \n                    . Accessed 21 Dec 2016."},{"key":"563_CR48","unstructured":"Ghana Statistical Service. Summary report of final results. 2012. \n                        http:\/\/www.statsghana.gov.gh\/docfiles\/2010phc\/Census2010_Summary_report_of_final_results.pdf\n                        \n                    . Accessed 16 Dec 2016."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0563-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0563-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0563-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T02:58:47Z","timestamp":1505876327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0563-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0563-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]}}}